exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089269 RNA Name: hsa-miR-642a-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 45674943 End Site(bp): 45674964 External Links: hsa-miR-642a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AFF4 chr5 132875395 132963634 - ARID3A chr19 925781 975939 + E2F3 chr6 20401879 20493714 + GFOD1 chr6 13357830 13487662 - HIF1AN chr10 100529072 100559998 + MAP3K12 chr12 53479669 53500063 - MAPKAPK2 chr1 206684944 206734283 + MDK chr11 46380756 46383837 + PPP6R1 chr19 55229779 55259017 - SIK2 chr11 111602449 111730855 + SLC7A2 chr8 17497088 17570573 + SYVN1 chr11 65121780 65134533 - TMED10 chr14 75131469 75176612 - TMEM30B chr14 61277370 61281761 - UBR3 chr2 169827454 170084131 + VAT1 chr17 43014607 43025123 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004832.5 chr22 30420512 30420912 + AC007952.4 chr17 19112000 19112636 - AC010327.5 chr19 55216660 55221616 + AC016876.2 chr17 7581964 7584086 - AL645465.1 chr1 244375100 244409592 - MIR34AHG chr1 9148011 9198906 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - ZFAS1 chr20 49278178 49299600 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.